A plenty of studies showed that GLUT1 is involved in the progression of cancer cell [50–52], and silencing Glut1 might enhance anticancer effect of chemotherapeutic agents in triple-negative breast cancer (TNBC) cell lines [53]. This evidence concerns the gene SLC2A1 and triple-negative breast carcinoma.